Tumors that acquire resistance to low-dose metronomic cyclophosphamide retain sensitivity to maximum tolerated dose cyclophosphamide. - Wikidata - wikimedia - TriplyDB

Tumors that acquire resistance to low-dose metronomic cyclophosphamide retain sensitivity to maximum tolerated dose cyclophosphamide.

Tumors that acquire resistance to low-dose metronomic cyclophosphamide retain sensitivity to maximum tolerated dose cyclophosphamide.

http://www.wikidata.org/entity/Q34497992

about

Pigment epithelium-derived factor expression prolongs survival and enhances the cytotoxicity of low-dose chemotherapy in castration-refractory prostate cancer.Metronomic cyclophosphamide schedule-dependence of innate immune cell recruitment and tumor regression in an implanted glioma model Moving forward with metronomic chemotherapy: meeting report of the 2nd International Workshop on Metronomic and Anti-Angiogenic Chemotherapy in Paediatric Oncology.The interconnectedness of cancer cell signaling.Analysis of acquired resistance to metronomic oral topotecan chemotherapy plus pazopanib after prolonged preclinical potent responsiveness in advanced ovarian cancer.Metronomic methotrexate and cyclophosphamide after carboplatin included adjuvant chemotherapy in triple negative breast cancer: a phase III study.Concentration- and schedule-dependent effects of chemotherapy on the angiogenic potential and drug sensitivity of vascular endothelial cells.The pharmacological bases of the antiangiogenic activity of paclitaxel.VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide.Metronomic chemotherapy: possible clinical application in advanced hepatocellular carcinoma Cancer subclonal genetic architecture as a key to personalized medicine.Treatment-induced host-mediated mechanisms reducing the efficacy of antitumor therapies.Metronomics: towards personalized chemotherapy?A systematic literature analysis of correlative studies in low-dose metronomic chemotherapy trials.Emerging roles of regulatory T cells in tumour progression and metastasis.In vivo passage of human prostate cancer cells in mice results in stable gene expression changes affecting numerous cancer-associated biological processes.Preclinical analysis of resistance and cross-resistance to low-dose metronomic chemotherapy.Impact of CTLA-4 blockade in conjunction with metronomic chemotherapy on preclinical breast cancer growth.Limiting the development of anti-cancer drug resistance in a spatial model of micrometastases Phase I lead-in and subsequent randomized trial assessing safety and modulation of regulatory T cell numbers following a maximally tolerated dose doxorubicin and metronomic dose cyclophosphamide combination chemotherapy protocol in tumour-bearing do Coadministration of epithelial junction opener JO-1 improves the efficacy and safety of chemotherapeutic drugs.Safety and therapeutic effect of metronomic chemotherapy with cyclophosphamide and celecoxib in advanced breast cancer patients.Resistance to metronomic chemotherapy and ways to overcome it.Overcoming intratumor heterogeneity of polygenic cancer drug resistance with improved biomarker integration Tumor dynamics in response to antiangiogenic therapy with oral metronomic topotecan and pazopanib in neuroblastoma xenografts.Toward maximizing immunotherapy in metastatic castration-resistant prostate cancer - rationale for combinatorial approaches using chemotherapy Dose Response of MTLn3 Cells to Serial Dilutions of Arsenic Trioxide and Ionizing Radiation.A Comprehensive Gene Expression Analysis of Resistance Formation upon Metronomic Cyclophosphamide Therapy.Metronomic chemotherapy following the maximum tolerated dose is an effective anti-tumour therapy affecting angiogenesis, tumour dissemination and cancer stem cells.Is There an Opportunity for Current Chemotherapeutics to Up-regulate MIC-A/B Ligands?First-line metronomic chemotherapy in a metastatic model of spontaneous canine tumours: a pilot study.Thrombospondin-targeting TAX2 peptide impairs tumor growth in preclinical mouse models of childhood neuroblastoma.

P2860

Q33720164-736ADA2B-FC39-4E47-B855-44124F2CF953 Q34173568-E12B71A8-B501-48D4-BF7F-2C731C1D9B05 Q35116804-2C7DB332-E47B-47AB-B9FC-E91D7D0F4EC2 Q35669733-494F4D95-AC1B-4881-9ADD-FCB85C04F929 Q35966821-A078FBDB-FC31-4875-BF5A-FF4A9F79401F Q36352501-08962D77-9E4F-4179-81D0-EBA9AE75CC8E Q36678312-82D8115E-5571-4A11-A64C-90DCA59A60A6 Q36927558-544F4C4B-4693-460A-873C-C3C0116430E9 Q37111160-B379C045-B556-4115-8BAF-DB0D9EF0778F Q37236004-06C62F75-A907-435A-BA40-AD1E971BDDD3 Q37448116-4C8DCEEF-9F90-4225-A328-03057601758C Q38092582-6115FEF7-E769-49FB-B29D-B8FDD046C7B9 Q38218923-2D0FD592-5B6D-4E02-9DD6-EEC4BB729595 Q38249998-5D592EC8-69B9-456A-B4B8-3AAAF46B5CF8 Q38264092-22FB514D-C566-43D9-8D11-B5B5C539F7E7 Q38480926-F46D7A38-D630-49E6-8AD9-CB26062A9104 Q38489591-4E5E9A96-13E2-4179-B6E2-CA88F4600F8D Q38722809-42BFA08B-CF4E-420F-8581-574FFC3755D3 Q38738084-13F89D65-4AB9-4E77-8324-4122926A7B72 Q38947623-90EDD519-F017-4795-BDC5-64AB7E0E7619 Q39358604-70418598-972F-43A4-A599-F4F6EDB2EA7C Q39455513-FB5EFE52-8B47-4961-8B91-84A6C94DE484 Q40448516-FA6E6852-DA5D-46F3-9BA1-4473D0F598BC Q41879186-B94A858F-C95F-4018-89B4-70EB16D96B57 Q41912972-69FD2882-D2EE-40C7-8109-6DD7E51F55D3 Q42180889-15D27C71-6DA5-41F7-9B7E-A09AE9DC4282 Q43242926-48216943-E8B7-47BD-8C64-C5F98CEE499D Q43246662-CF0E33FD-3AB6-4CD3-9046-A258F16790B7 Q44084942-4EBF0B19-2839-44AF-B6E7-CEED6A7B0DA7 Q47110491-89FD2EDC-B549-4A18-92CB-0187D1087C8E Q48686558-B1D57B3F-7A93-4614-A4D2-032C188E314C Q51328292-EA9165EA-0A21-439A-89F0-0C8F185D2852

P2860

Tumors that acquire resistance to low-dose metronomic cyclophosphamide retain sensitivity to maximum tolerated dose cyclophosphamide.

http://www.wikidata.org/entity/Q34497992

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

name

Tumors that acquire resistance ...... lerated dose cyclophosphamide.

@ast

Tumors that acquire resistance ...... lerated dose cyclophosphamide.

@en

Tumors that acquire resistance ...... lerated dose cyclophosphamide.

@nl

type

label

Tumors that acquire resistance ...... lerated dose cyclophosphamide.

@ast

Tumors that acquire resistance ...... lerated dose cyclophosphamide.

@en

Tumors that acquire resistance ...... lerated dose cyclophosphamide.

@nl

prefLabel

Tumors that acquire resistance ...... lerated dose cyclophosphamide.

@ast

Tumors that acquire resistance ...... lerated dose cyclophosphamide.

@en

Tumors that acquire resistance ...... lerated dose cyclophosphamide.

@nl

P1433

Q34497992-81633A36-2AD0-49D5-ACBF-D352BE50D765

P1476

Q34497992-363E2AC5-8C7F-477A-831A-56527AE4D26F

P2093

Q34497992-663B5B4D-3C3F-4B70-B01F-C0D04DB720B5

Q34497992-7F2E0D09-1163-40D5-8F09-6E30ED9BC6C5

Q34497992-9188F8DF-FEAB-41D8-8831-4F94B1583CC4

Q34497992-A708145E-33B4-479A-B4A5-EF60DA78EDE1

Q34497992-B4BD5096-2A8E-4B5B-B5CE-DAAC65C9E6B4

Q34497992-DBDD2D40-AA22-4B3C-B37F-56A7C3E4E50E

Q34497992-FB89616C-4564-41EC-B671-97719093AFA6

P2860

Q34497992-005F1423-F4DB-42D2-9EB1-B0DAFF9A5364

Q34497992-0AA17897-9CC3-4E19-BC56-394ABFB2832D

Q34497992-0E8C0488-7B2B-43B9-A7E3-68BE2F2DB3A8

Q34497992-162D648B-DBEE-498F-B708-8C50FF4C4FF2

Q34497992-20CE3E68-69F1-4585-861F-92A07338C28C

Q34497992-22B64BB6-93F6-4DB6-B1A9-584533877D17

Q34497992-257BD4DB-9FCC-4524-AE0F-54DDA22B9A10

Q34497992-2EA033DE-15B9-4347-AF98-92E939E326C5

Q34497992-3832C4D3-E3A0-4319-AE6C-8AEF7E91C317

Q34497992-3A076C33-D4A0-43A2-8A6D-4A2C7AC6F310

P304

Q34497992-1CEC18DA-FA57-4F90-8805-848F50196487

P31

Q34497992-0274A4F5-5DE7-4614-9D9E-197D71C19BFB

P356

Q34497992-2D6A76B4-DDF3-42B9-86CD-17D0685AC3DB

P433

Q34497992-9CB42758-C8DF-4DB3-AB3D-56204693E757

P478

Q34497992-C758BBF6-1372-46F9-B757-004B4FE8791A

P577

Q34497992-C74CDD1E-2E0D-46D9-ADA9-9921BA4BC7A1

P5875

Q34497992-119FD448-B8AA-4CD1-B642-CBE01109C066

P698

Q34497992-C7BA107C-0D11-4277-BB1C-5B588EE61098

P932

Q34497992-DAAEEABC-0E29-4BCA-8FC8-4C7BB88D8F9F

P356

P1433

P1476

Tumors that acquire resistance ...... lerated dose cyclophosphamide.

@en

P2093

Andrew Kouri

http://www.w3.org/2001/XMLSchema#string

Annabelle Chow

http://www.w3.org/2001/XMLSchema#string

Giulio Francia

http://www.w3.org/2001/XMLSchema#string

Robert S Kerbel

http://www.w3.org/2001/XMLSchema#string

Shan Man

http://www.w3.org/2001/XMLSchema#string

Urban Emmenegger

http://www.w3.org/2001/XMLSchema#string

Yuval Shaked

http://www.w3.org/2001/XMLSchema#string

P2860

Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity

Modes of resistance to anti-angiogenic therapy

Clinical trial update: International Breast Cancer Study Group

A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung

Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: National Surgical Adjuvant Study for Breast Cancer 01 Trial

Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer

Angiogenesis in life, disease and medicine

Tumor angiogenesis

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

Heterogeneous vascular dependence of tumor cell populations

P304

40-48

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1593/NEO.101174

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P577

2011-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49765901

http://www.w3.org/2001/XMLSchema#string

P698

21245939

http://www.w3.org/2001/XMLSchema#string

P932

3022427

http://www.w3.org/2001/XMLSchema#string